PIK3CA and breast carcinoma: Therefore, the development of PI3Kγ inhibitors is expected to shift the development strategy of PI3K inhibitors from the concept of “targeted therapy” to “immunotherapy”, indicating that it has a wide application in the combined immunosuppression treatment of breast cancer (27, 28).